Institutional members access full text with Ovid®

Share this article on:

Prevention of Venous Thromboembolism in Hospitalized Patients With Inflammatory Bowel Disease

Chande, Nilesh MD

doi: 10.1097/MIB.0b013e31827e7a0f
Cochrane Review

Abstract: Venous thromboembolism is a relatively common and potentially serious complication in inpatients with inflammatory bowel disease (IBD). There are a number of pathophysiologic mechanisms for venous thromboembolism that are specific to patients with IBD that may be active. The use of anticoagulants for prophylaxis against venous thromboembolism in hospitalized patients with IBD needs to be balanced against the potential for worsening of rectal bleeding. Evidence from randomized trials suggests that heparin and low–molecular weight heparin are generally safe to use in patients with active IBD, and a number of guidelines support their use for thromboprophylaxis in this patient population.

Article first published online 4 February 2013

Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada.

Reprints: Nilesh Chande, MD, Room E1-423A, London Health Sciences Centre, Victoria Hospital, 800 Commissioners Road East, London, Ontario, Canada (e-mail: nilesh.chande@lhsc.on.ca).

The author has no financial or conflicts of interest to disclose.

Received June 02, 2012

Accepted June 12, 2012

© Crohn's & Colitis Foundation of America, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website